[Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma].
The post-diagnostic changes in the free to total PSA ratio in the serum of patients with prostate carcinoma, after the initiation of endocrine treatment were examined. Two-week pretreatment with either chlormadinone acetate (100 mg/day) or flutamide (375 ng/day) was administered orally to 14 patients with newly diagnosed advanced prostate carcinoma (clinical stage was C in 2, Dl in 1 and D2 in 11). Then the LH-RH analogue was injected. Total and free PSA in the serum of these patients were measured every 4 weeks by the Ab bead PSA (Eiken) and the recently developed assay for free PSA by Eiken, respectively. The follow-up period ranged from 3 to 9 months with a median of 6 months. Levels of both total and free PSAs decreased significantly following the endocrine treatment, while free to total PSA ratio at 4 to 16 weeks after the start of LH-RH analogue was increased significantly compared to the pretreatment level (p < 0.05). These findings suggest that the rate of decrease of complex PSA during the first 4 months after the beginning of treatment may exceed that of free PSA in the serum of patients with advanced prostate carcinoma initially treated with endocrine therapy.
Sumi
S
S
Department of Urology, Dokkyo University School of Medicine.
Umeda
H
H
Yano
M
M
Koga
F
F
Arai
K
K
Imai
T
T
Hosoya
Y
Y
Maeda
S
S
Honda
M
M
Suzuki
T
T
Yoshida
K
K
D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000097:blood*; D002715:Chlormadinone Acetate / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005485:Flutamide / Q000008:administration & dosage*; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D015592:Immunoradiometric Assay / Q000379:methods; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D011933:Reagent Kits, Diagnostic
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D011933:Reagent Kits, Diagnostic; D002715:Chlormadinone Acetate; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D017430:Prostate-Specific Antigen